The company unveiled detailed findings from the Phase III SURMOUNT-OSA program, showing that its blockbuster weight-loss drug Zepbound (tirzepatide) could significantly improve disease severity in patients with moderate-to-severe obstructive sleep apnea and obesity.
Tag Archive for: Phase III trial
Gilead Sciences’ antiviral demonstrated 100% efficacy for HIV prevention in cisgender women in Phase III trial results announced Thursday.
AstraZeneca on Tuesday announced that its AKT inhibitor Truqap, when used in combination with paclitaxel, failed to meet its primary efficacy endpoint in the Phase III CAPItello-290 study in patients with metastatic triple-negative breast cancer.
Full data from the FLOW study show that Novo Nordisk’s top-selling GLP-1 receptor agonist semaglutide can significantly reduce the risk of death by 20% in diabetes patients with chronic kidney disease.
After missing their initial target in March 2024, Eisai and Biogen have initiated a rolling BLA for a subcutaneous maintenance formulation of Leqembi, which could offer a more convenient dosing schedule for Alzheimer’s disease patients.
AstraZeneca’s blockbuster BTK inhibitor Calquence significantly improved progression-free survival when used as a frontline treatment in patients with mantle cell lymphoma, according to Thursday’s late-stage results.
Data from the Phase III LUNA 3 study on Tuesday showed that Sanofi’s BTK inhibitor rilzabrutinib significantly improved durable platelet response in patients with chronic immune thrombocytopenia.
Cerevel Therapeutics reported positive data from its Phase III TEMPO-3 trial, showing that tavapadon can significantly improve symptom control in patients with Parkinson’s disease.
Roche said Monday that its bispecific T-cell engager Columvi improved survival in a Phase III lymphoma trial, clearing the drugmaker to seek a full, expanded label that could drive sales growth.
Bristol Myers Squibb on Saturday unveiled interim data from the Phase III open-label EMERGENT-4 study, showing that the investigational antipsychotic KarXT (xanomeline and trospium) can elicit significant and sustained symptom improvement in patients with schizophrenia.